SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+7.96%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$1.32B
AUM Growth
+$1.32B
(+9.9%)
Cap. Flow
+$196M
Cap. Flow
% of AUM
14.83%
Top 10 Holdings %
Top 10 Hldgs %
42.53%
Holding
111
New
24
Increased
21
Reduced
23
Closed
30
Top Buys
| 1 |
NovoCure
NVCR
|
$81.6M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$65.8M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$46.1M |
| 4 |
Integra LifeSciences
IART
|
$28.9M |
| 5 |
AstraZeneca
AZN
|
$26.8M |
Top Sells
| 1 |
Sanofi
SNY
|
$35.3M |
| 2 |
IDEAYA Biosciences
IDYA
|
$33.2M |
| 3 |
Revolution Medicines
RVMD
|
$22M |
| 4 |
10x Genomics
TXG
|
$21.5M |
| 5 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$15.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
AnaptysBio
ANAB
$573M
| $5.48M | 0.34% |
+414,000
| New | +$5.48M |
|
52
Erasca
ERAS
$460M
| $5.43M | 0.34% |
2,162,162
| – | – |
|
53
Edgewise Therapeutics
EWTX
$1.57B
| $4.89M | 0.31% |
+183,300
| New | +$4.89M |
|
54
Vericel Corp
VCEL
$1.78B
| $4.43M | 0.28% |
+80,696
| New | +$4.43M |
|
55
Crinetics Pharmaceuticals
CRNX
$3.07B
| $4.35M | 0.27% |
+85,000
| New | +$4.35M |
|
56
ESSA Pharma
EPIX
$11.2M
| $4.05M | 0.25% |
2,262,026
-2,026,141
| -47% | -$3.63M |
|
57
InspireMD
NSPR
$100M
| $3.62M | 0.23% |
1,378,128
| – | – |
|
58
Rocket Pharmaceuticals
RCKT
$353M
| $3.41M | 0.21% |
+271,659
| New | +$3.41M |
|
59
Madrigal Pharmaceuticals
MDGL
$9.73B
| $3.36M | 0.21% |
+10,900
| New | +$3.36M |
|
60
Replimune Group
REPL
$452M
| $3.18M | 0.2% |
+262,500
| New | +$3.18M |
|
61
Apogee Therapeutics
APGE
$2.24B
| $3.17M | 0.2% |
+70,000
| New | +$3.17M |
|
62
CalciMedica
CALC
$43.5M
| $2.78M | 0.17% |
783,904
| – | – |
|
|
MREO
63
Mereo BioPharma
MREO
$280M
| $2.75M | 0.17% |
786,953
-60,000
| -7% | -$210K |
|
64
Y-mAbs Therapeutics
YMAB
$389M
| $2.74M | 0.17% |
349,982
-50,000
| -13% | -$392K |
|
65
Establishment Labs
ESTA
$1.17B
| $2.74M | 0.17% |
59,400
| – | – |
|
66
Bausch + Lomb
BLCO
$5.18B
| $2.18M | 0.14% |
120,500
-191,500
| -61% | -$3.46M |
|
67
MDxHealth
MDXH
$176M
| $2.02M | 0.13% |
851,688
-253,312
| -23% | -$600K |
|
68
Enliven Therapeutics
ELVN
$1.23B
| $1.7M | 0.11% |
75,405
-164,300
| -69% | -$3.7M |
|
69
Regeneron Pharmaceuticals
REGN
$60.8B
| $1.64M | 0.1% |
+2,300
| New | +$1.64M |
|
|
TECX
70
Tectonic Therapeutic, Inc. Common Stock
TECX
$317M
| $1.47M | 0.09% |
+31,841
| New | +$1.47M |
|
71
Adverum Biotechnologies
ADVM
$63M
| $1.34M | 0.08% |
287,246
| – | – |
|
|
WHWK
72
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $1.05M | 0.07% |
333,227
| – | – |
|
|
ABVX
73
Abivax
ABVX
$6.16B
| $915K | 0.06% |
125,000
| – | – |
|
74
Viridian Therapeutics
VRDN
$1.53B
| $872K | 0.05% |
45,500
-49,500
| -52% | -$949K |
|
75
GSK
GSK
$78.1B
| $342K | 0.02% |
10,110
-27,390
| -73% | -$926K |
|